Danish Supreme Court upholds Spinraza decision, denies compensation claims

Doctors were right to deny treatment using Biogen’s drug Spinraza to children with muscular atrophy, the Danish Supreme Court has concluded.

The Danish Supreme Court | Photo: Jens Dresling

The Danish Medicines Council has previously concluded that Biogen’s muscular atrophy treatment Spinraza is not worth the money for a wider group of patients, as its high price is not in line with its effect.

Now, the Danish Supreme Court has upheld that ruling, saying that doctors were in the right when they did not treat six children with muscular atrophy with Biogen’s drug Spinraza in 2017, as they were acting to the best of their abilities and in line with the applicable legislation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs